Ngaphezu kwe-9 yeebhiliyoni zeerandi ichiza leenkwenkwezi iQilu yimveliso yokuqala yasekhaya ukuxelwa ukuba yenziwe.

1.Ngaphezu kwe-9 yeebhiliyoni zeerandi ichiza leenkwenkwezi iQilu yimveliso yokuqala yasekhaya ukuxelwa ukuba yenziwe.I-Qilu pharmaceutical ifumene ukwamkelwa kweCDE kuluhlu lwesicelo se-Aflibercept intraocular injection solution engeniswe ludidi olutsha lwechiza 3.3, oluyimveliso yokuqala exeliweyo ye-Aflibercept yebhayoloji efana neyeza e-China.

2.Ngomhla we-11 kuMeyi, isicelo soluhlu lwesisombululo se-levosalbuterol hydrochloride se-atomized inhalation esingeniswe ngu-Hunan Warner Pharmaceutical Co., Ltd. kunye necandelo lesi-3 leyeza elenziwe lafana nelo lamkelekile yiCDE.I-Levosalbuterol isetyenziswa ngokuqhelekileyo i-β 2 receptor agonists.Ngokutsho kwedatha ye-Intranet, ukuthengiswa kwe-terminal l-salbutamol Hydrochloride Aerosol Inhalation Solution kumaziko onyango karhulumente e-China ngo-2021 yayimalunga ne-200 yezigidi ze-yuan, kunye nokunyuka konyaka ngaphezu kwe-3209%.

3.Inaliti yesodium ye-Enoxaparin ingeniswe kwishishini lesihlanu elivavanyiweyo.Ukusondela kokuthenga okuphakathi kwenze abadlali abakwibala le-heparin bangazinzi.Ngokutsho kwedatha ye-Intranet, ukuthengiswa kwe-terminal ye-heparin kunye ne-molekyuli ephantsi yobunzima be-heparin amalungiselelo kumaziko ezonyango aseTshayina adlula i-yuan ye-12 yeebhiliyoni ngo-2021, kunye nokunyuka konyaka-ngonyaka kwe-12.98%.Phakathi kweemveliso eziphezulu ze-10, inaliti ye-sodium ye-enoxaparin yaqhubeka ikhokela, kwaye ukuthengiswa kweemveliso ze-9 kwanda kakhulu.Phakathi kwamashishini amahlanu okudibanisa amalungiselelo e-Heparin API, i-Heprui, izabelo ze-Jianyou kunye ne-Changshan amayeza akhokele ingeniso yeshishini le-Heparin kwi-2021, eyenza imeko ye-tripartite.

4.Umsitho wokuphehlelelwa kwezibuko lokungenisa amachiza eZhongshan kunye nebhetshi yokuqala yokukhutshwa kwelungelo lokungeniswa kweziyobisi kwamanye amazwe wawubanjelwe kwizibuko laseZhongshan iSinotrans Wharf kwiZowuni yoPhuhliso lweTotshi yaseZhongshan, kwiPhondo laseGuangdong.Ibhetshi yokuqala ye "cefotaxime sodium" kunye "nomgubo weZhupo wabantwana" ongeniswe nguGuangdong Jincheng Jinsu Pharmaceutical Co., Ltd. kunye neHong Kong Baohetang Pharmaceutical Co., Ltd. igqibe ngempumelelo ukukhutshwa kwezithethe, ibe yibhetshi yokuqala yamachiza angeniswa kwamanye amazwe ukuba abe icocwe kwizibuko.

5.Ngomhla we-25 kaMeyi, i-aosakang iphinde yafaka isicelo sokuthengiswa kweklasi ye-2.2 yamachiza amatsha e-dextrolanzoprazole yokujova.I-Takeda yamayeza inokulungiswa ngomlomo kuphela kwe-dextrolanzolanzole.Ngo-2021, ithengise ngaphezulu kwe-50.7 yeebhiliyoni zeedola (malunga ne-400 yezigidi zeedola zaseMelika) kwihlabathi jikelele.Okwangoku, akukho mvumelwano yokungenisa okanye yasekhaya yeemveliso ezinxulumene nolu hlobo kwimarike yasekhaya.

6.NgoMeyi 25, iZhejiang Puli Pharmaceutical Co., Ltd. ingenise isicelo seklinikhi yeklasi ye-2.2 ichiza elitsha le-memantine hydrochloride granules.I-Memantine lolona didi luthengiswa kakhulu lwamachiza alwa ukudemeka kwengqondo kumachiza enkqubo yemithambo-luvo.Okwangoku, kukho ii-capsules, iipilisi kunye nee-agent ze-oral liquid agents kwimarike, kwaye akukho granules ezivunyiweyo zoluhlu okanye ukungenisa.I-Puli lishishini lokuqala ukufaka isicelo seklinikhi ye-granules.

7.NgoMeyi 27, i-Shandong entsha yexesha le-Pharmaceutical Co., Ltd. ingenise isicelo soluhlu lweentlobo ezine zokuxelisa iipilisi ze-etoxaban toluenesulfonate.Okwangoku, alikho ichiza lasekhaya elenziwe afana nalawo aveliswe ngumenzi wale mveliso kwimarike.I-Hainan Xiansheng Pharmaceutical Co., Ltd., iNanjing Zhengda Tianqing Pharmaceutical Co., Ltd. kunye neNanjing Hailing Pharmaceutical Co., Ltd. yeYangzijiang Pharmaceutical Group ingenise imveliso, ephononongwayo kunye nokuvunywa, kunye nengxabano malunga negeneric yokuqala. iyeza liya lisiba bukhali ngakumbi.I-Edoxaban yinto ekhethiweyo Xa inhibitor ephuhliswe yi-Sankyo yokuqala.Yavunywa okokuqala kwi-venous thromboembolism eJapan ngo-2011, kwaye emva koko inani lezalathisi ezintsha zamkelwa.Ngo-2021, intengiso yehlabathi ifikelele kwi-189.4 yeebhiliyoni zeedola (malunga ne-1.5 yeebhiliyoni zeedola zaseMelika).

JinDun Medicalinentsebenziswano yexesha elide yophando lwezenzululwazi kunye neteknoloji yokuxhunyelelwa kwiiyunivesithi zaseTshayina.Ngezixhobo zonyango ezityebileyo zikaJiangsu, inobudlelwane bexesha elide kunye neIndiya, iSoutheast Asia, iSouth Korea, iJapan kunye nezinye iimarike.Ikwabonelela ngeenkonzo zentengiso kunye nentengiso kuyo yonke inkqubo ukusuka phakathi ukuya kwimveliso egqityiweyo ye-API.Sebenzisa izibonelelo eziqokelelweyo zeJinDun Chemical kwikhemistri yefluorine ukubonelelaiinkonzo ezizodwa zokwenza imichizakumaqabane.Ukubonelela ngenkqubo yokuveliswa kwezinto ezintsha kunye neenkonzo zophando lokungcola kubathengi abajoliswe kuyo.